Skip to main content

Table 1 The prognostic values of immune landscape markers in EC

From: The immune landscape of esophageal cancer

Biomarker Prognostic value
Clinical survival Tumor stage Differentiation grade Metastasis Response to chemotherapy Response to immunotherapy
MAGE-A11 − [63] N/A N/A + [63] N/A N/A
NY-ESO-1 N/A N/A N/A N/A N/A Vaccination:− [24]
TMB N/A N/A N/A N/A N/A PD-1 inhibition: + [18]
MANA N/A N/A N/A N/A N/A PD-1 inhibition: + [18]
PD-L1 N/A N/A N/A N/A N/A PD-1 inhibition: + [18]
PD-1 N/A + [67] N/A + [67] N/A N/A
CTLA-4 − [28] N/A N/A N/A N/A N/A
IDO1 − [32, 70] N/A N/A N/A − [68] N/A
PD-L1 + IDO1 − [68, 69] N/A N/A N/A − [69] N/A
VISTA + [27] N/A N/A N/A N/A N/A
TGF-β N/A N/A N/A N/A − [72] N/A
TGF-β + IL-10 N/A + [71] N/A N/A N/A N/A
IL-6 N/A N/A N/A N/A − [50] N/A
CD80 or CD86 N/A − [71, 73] − [71, 73] N/A N/A N/A
CD1a+ cells N/A N/A − [73] N/A N/A N/A
CD8+ TILs + [75] N/A N/A − [75] + [75] N/A
CD8+/Foxp3+ ratio + [29] N/A N/A N/A N/A N/A
CCL4highCCL20low + [52] N/A N/A N/A N/A N/A
M2-like TAMs − [48, 49] N/A N/A N/A N/A N/A
MDSCs N/A + [50, 51] N/A N/A − [50] N/A
  1. +, positively correlated; −, negatively correlated; N/A not available
  2. EC esophageal cancer, MAGE-A11 melanoma-associated antigen A11, NY-ESO-1 New York esophageal squamous cell carcinoma 1, TMB tumor mutation burden, MANA mutation-associated neoantigen, PD-L1 programmed death-ligand 1, PD-1 programmed cell death protein 1, CTLA-4 cytotoxic T lymphocyte-associated protein 4, IDO1 indoleamine 2,3-dioxygenase 1, TGF-β transforming growth factor-β, IL-10 interleukin-10, IL-6 interleukin-6, TILs tumor-infiltrating lymphocytes, TAM tumor-associated macrophage, MDSC myeloid-derived suppressor cell